| Paul Henry Harford, MD | |
|
1301 W 38th St Ste 700, Austin, TX 78705-1016 | |
| (512) 324-3340 | |
| Not Available |
| Full Name | Paul Henry Harford |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 41 Years |
| Location | 1301 W 38th St Ste 700, Austin, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710902036 | NPI | - | NPPES |
| 136848208 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | G5149 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Dell Seton Med Center At The University Of Tx | Austin, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Seton Family Of Doctors | 0941333280 | 663 |
News Archive
SARS-CoV-2 is the causative agent of COVID-19 disease, currently raging across the world. The virus has now infected more than 43.89 million individuals and claimed over 1.16 million lives. The study titled, "Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects," is released on the preprint server bioRxiv* in October 2020.
A substantial number of people with eating disorders, such as anorexia nervosa have a chronic course. They are severely underweight and have a high likelihood of dying from malnutrition. No treatment has been found that helps people who are chronically ill. Now, a new study sheds light on the reason that some people have poor outcome.
Genetically analysing lesions in the food pipe could provide an early and accurate test for oesophageal cancer, according to research led by Queen Mary University of London, Academic Medical Center in Amsterdam and Arizona State University.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the company has submitted a new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 5 days ago
| Entity Name | Shannon Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770587149 PECOS PAC ID: 0840103727 Enrollment ID: O20031222000702 |
News Archive
SARS-CoV-2 is the causative agent of COVID-19 disease, currently raging across the world. The virus has now infected more than 43.89 million individuals and claimed over 1.16 million lives. The study titled, "Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects," is released on the preprint server bioRxiv* in October 2020.
A substantial number of people with eating disorders, such as anorexia nervosa have a chronic course. They are severely underweight and have a high likelihood of dying from malnutrition. No treatment has been found that helps people who are chronically ill. Now, a new study sheds light on the reason that some people have poor outcome.
Genetically analysing lesions in the food pipe could provide an early and accurate test for oesophageal cancer, according to research led by Queen Mary University of London, Academic Medical Center in Amsterdam and Arizona State University.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the company has submitted a new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 5 days ago
| Entity Name | Austin Critical Care Specialists Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447435805 PECOS PAC ID: 1052497187 Enrollment ID: O20080328000560 |
News Archive
SARS-CoV-2 is the causative agent of COVID-19 disease, currently raging across the world. The virus has now infected more than 43.89 million individuals and claimed over 1.16 million lives. The study titled, "Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects," is released on the preprint server bioRxiv* in October 2020.
A substantial number of people with eating disorders, such as anorexia nervosa have a chronic course. They are severely underweight and have a high likelihood of dying from malnutrition. No treatment has been found that helps people who are chronically ill. Now, a new study sheds light on the reason that some people have poor outcome.
Genetically analysing lesions in the food pipe could provide an early and accurate test for oesophageal cancer, according to research led by Queen Mary University of London, Academic Medical Center in Amsterdam and Arizona State University.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the company has submitted a new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 5 days ago
| Entity Name | Seton Family Of Doctors |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588997233 PECOS PAC ID: 0941333280 Enrollment ID: O20100806000260 |
News Archive
SARS-CoV-2 is the causative agent of COVID-19 disease, currently raging across the world. The virus has now infected more than 43.89 million individuals and claimed over 1.16 million lives. The study titled, "Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects," is released on the preprint server bioRxiv* in October 2020.
A substantial number of people with eating disorders, such as anorexia nervosa have a chronic course. They are severely underweight and have a high likelihood of dying from malnutrition. No treatment has been found that helps people who are chronically ill. Now, a new study sheds light on the reason that some people have poor outcome.
Genetically analysing lesions in the food pipe could provide an early and accurate test for oesophageal cancer, according to research led by Queen Mary University of London, Academic Medical Center in Amsterdam and Arizona State University.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the company has submitted a new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul Henry Harford, MD 1301 W 38th St Ste 700, Austin, TX 78705-1016 Ph: (512) 324-3340 | Paul Henry Harford, MD 1301 W 38th St Ste 700, Austin, TX 78705-1016 Ph: (512) 324-3340 |
News Archive
SARS-CoV-2 is the causative agent of COVID-19 disease, currently raging across the world. The virus has now infected more than 43.89 million individuals and claimed over 1.16 million lives. The study titled, "Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects," is released on the preprint server bioRxiv* in October 2020.
A substantial number of people with eating disorders, such as anorexia nervosa have a chronic course. They are severely underweight and have a high likelihood of dying from malnutrition. No treatment has been found that helps people who are chronically ill. Now, a new study sheds light on the reason that some people have poor outcome.
Genetically analysing lesions in the food pipe could provide an early and accurate test for oesophageal cancer, according to research led by Queen Mary University of London, Academic Medical Center in Amsterdam and Arizona State University.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the company has submitted a new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
› Verified 5 days ago
Dr. Tatiana B. Jacobson, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 5656 Bee Caves Rd. Bldg C Ste. 102, Austin, TX 78746 Phone: 512-323-5465 Fax: 512-327-1390 | |
Preeti Venkatraman, M.B.B.S. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 E 15th St, Austin, TX 78701 Phone: 512-324-7000 | |
Pritesh Harish Gandhi, M.D., M.P.H. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1101 Camino La Costa, Austin, TX 78752 Phone: 512-684-1832 | |
Dr. Joshua Lane Davis, D.O. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1004 W 32nd St Unit 300, Austin, TX 78705 Phone: 512-324-3440 | |
Dr. Analicia Alvarado, MD Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 1500 Red River St, Austin, TX 78701 Phone: 512-324-7000 | |
Dr. Grace Marie Grant-jennings, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 7000 North Mopac, Suite # 420, Austin, TX 78731 Phone: 512-482-0045 Fax: 512-476-9892 | |
Dr. Debra Ann Patt, MD, MPH Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 6204 Balcones Dr, Austin, TX 78731 Phone: 512-427-9400 Fax: 512-342-2723 |